title: Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides.
abstract: The tumor-rejection antigen SART3 possesses two antigenic epitopes (SART3(109-118) and SART3(315-323)) capable of inducing HLA-A24-restricted and tumor-specific CTLs. To determine its safety and ability to generate antitumor immune responses, 12 patients with advanced colorectal cancer were administered s.c. vaccinations of these peptides. No severe adverse events were associated with the vaccinations. Significant levels of increased cellular immune responses to both HLA-A24+ colon cancer cells and the vaccinated peptide were observed in the postvaccination peripheral blood mononuclear cells in 7 of 11 and 7 of 10 patients tested, respectively, and the higher responses were observed in those patients vaccinated with the highest dose (3 mg/injection) of the peptides. These results encourage further development of SART3 peptide vaccine for colorectal cancer patients.
authors.affiliation: Department of Surgery, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830-0011, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Miyagi
authors.forename: N
authors.initials: N
authors.lastname: Imai
authors.forename: T
authors.initials: T
authors.lastname: Sasatomi
authors.forename: A
authors.initials: A
authors.lastname: Yamada
authors.forename: T
authors.initials: T
authors.lastname: Mine
authors.forename: K
authors.initials: K
authors.lastname: Katagiri
authors.forename: M
authors.initials: M
authors.lastname: Nakagawa
authors.forename: A
authors.initials: A
authors.lastname: Muto
authors.forename: S
authors.initials: S
authors.lastname: Okouchi
authors.forename: H
authors.initials: H
authors.lastname: Isomoto
authors.forename: K
authors.initials: K
authors.lastname: Shirouzu
authors.forename: H
authors.initials: H
authors.lastname: Yamana
authors.forename: K
authors.initials: K
authors.lastname: Itoh
mesh_terms: D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D000939:Epitopes / Q000276:immunology; D005260:Female; D015234:HLA-A Antigens / Q000276:immunology; D059871:HLA-A24 Antigen; D006801:Humans; D006969:Hypersensitivity, Immediate; D007111:Immunity, Cellular; D007073:Immunoglobulin E / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016601:RNA-Binding Proteins / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use*; D015996:Survival Rate; D013997:Time Factors
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D000939:Epitopes; D015234:HLA-A Antigens; D059871:HLA-A24 Antigen; D007074:Immunoglobulin G; D016601:RNA-Binding Proteins; C416530:SART3 protein, human; D007073:Immunoglobulin E